GlassScriptPhysician profile
Kaileen Yeh
NPI 1023542594
$6,795.11
in general payments reported to CMS, 2019-2025
19 companies · $908 in 2025
The $908 reported for 2025 was more than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $129 · 2020: $168 · 2021: $489 · 2022: $587 · 2023: $2,396 · 2024: $2,118 · 2025: $908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,423.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,422.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,319.86 | 2019-2025 | Hydrus Microstent, Clareon, Rocklatan |
| Abbvie INC. | $2,197.14 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Sight Sciences, INC. | $454.45 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Oyster Point Pharma, INC. | $388.39 | 2022-2025 | Tyrvaya, Ryzumvi |
| Astellas Pharma US INC | $291.05 | 2023-2024 | Izervay |
| Apellis Pharmaceuticals, INC. | $218.99 | 2022-2025 | Syfovre |
| Genentech USA, INC. | $154.03 | 2022-2024 | Vabysmo |
| Bausch & Lomb Americas INC. | $130.03 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Regeneron Healthcare Solutions, INC. | $113.96 | 2023-2025 | Eylea Hd, Eylea |
| Biotissue Holdings INC. | $98.93 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $52.36 | 2022-2023 | |
| Thea Pharma INC. | $45.77 | 2024-2025 | Iyuzeh |
| Carl Zeiss Meditec USA, INC. | $29.06 | 2024 | Cirrus Hd-Oct |
| Horizon Therapeutics Plc | $27.63 | 2023 | Tepezza |
| Amgen INC. | $25.07 | 2024 | Tepezza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $24.06 | 2024 | Rxsight Contact Lens, Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
| Dompe US, INC. | $22.61 | 2024 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $18.17 | 2024 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaileen Yeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.